B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 188 DKK 2.37% Market Closed
Market Cap: 14.9B DKK

Bavarian Nordic A/S
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bavarian Nordic A/S
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
B
Bavarian Nordic A/S
CSE:BAVA
Stock-Based Compensation
kr83.9m
CAGR 3-Years
33%
CAGR 5-Years
23%
CAGR 10-Years
12%
Genmab A/S
CSE:GMAB
Stock-Based Compensation
kr115.6m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Stock-Based Compensation
kr110.6m
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Stock-Based Compensation
€112.4m
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
53%
Bioporto A/S
CSE:BIOPOR
Stock-Based Compensation
kr1.1m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Saniona AB
STO:SANION
Stock-Based Compensation
kr3.7m
CAGR 3-Years
N/A
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Bavarian Nordic A/S
Glance View

Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.

BAVA Intrinsic Value
137.43 DKK
Overvaluation 27%
Intrinsic Value
Price
B

See Also

What is Bavarian Nordic A/S's Stock-Based Compensation?
Stock-Based Compensation
83.9m DKK

Based on the financial report for Sep 30, 2025, Bavarian Nordic A/S's Stock-Based Compensation amounts to 83.9m DKK.

What is Bavarian Nordic A/S's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
12%

Over the last year, the Stock-Based Compensation growth was -29%. The average annual Stock-Based Compensation growth rates for Bavarian Nordic A/S have been 33% over the past three years , 23% over the past five years , and 12% over the past ten years .

Back to Top